LUMIT
DEAD

Serial Number

79404481

Owner

LuMit Co., Ltd.

Attorney

Charles Y. Park

Filing Date

Oct 27, 2023

Add to watchlist:

No watchlists yet
View on USPTO

LUMIT Trademark

Serial Number: 79404481

LUMIT is a trademark filed by LuMit Co., Ltd. on October 27, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

LuMit Co., Ltd.

2-west, 37,

Entity Type: 03

Trademark Details

Filing Date

October 27, 2023

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical agents affecting peripheral nervous system; dietary fiber to aid digestion; pharmaceutical preparations for the prevention of disorders of the nervous system; cardiovascular pharmaceutical preparations; cardiovascular pharmaceuticals; pharmaceutical preparations for the treatment of cardiovascular disease; eye drops; allergy medications; dietetic food substances, namely, plant-derived bioactive compounds, mitochondria-targeted supplements, and functional nutraceuticals for cardiovascular, immune, and metabolic health adapted for medical use; bath preparations for medical purposes; diagnostic agents for medical use; slimming tea for medical purposes; pharmaceutical compositions for the prevention and treatment of mitochondrial disorders, metabolic imbalances, cardiovascular diseases, immune dysregulation, cancer, fibrosis, and neurodegenerative diseases; pharmaceutical preparations for enhancing mitochondrial bioenergetics to support cardiovascular function, regulate immune responses, prevent and treat cardiac fibrosis, and improve vascular and metabolic health; pharmaceutical preparations for the treatment of central nervous system (CNS) diseases; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for diagnosis of mitochondrial disorders, cardiovascular diseases, immune dysregulation, cancer progression, neurodegenerative progression, and metabolic imbalances; analgesic balm; nutraceuticals for therapeutic purposes in the nature of mitochondrial energy restoration, immune system modulation, endothelial function support, and fibrosis attenuation; nutraceutical preparations for therapeutic and medical purposes in the nature of cardiovascular protection, oxidative stress regulation, immune system enhancement, and cellular metabolism optimization; pharmaceutical preparations for the treatment of parkinson's disease; antimicrobials for dermatologic use; pharmaceutical preparations for treating epidermal problems; pharmaceutical preparation for skin care; pharmaceutical preparations for skin care; antihypertensives; anti-diabetic pharmaceuticals; anti-cancer preparations; anti-sarcoma preparations; anticoagulants; anti-cancer preparations in the nature of antineoplastics; anti-dermoinfectives; antidotes; antipyretic analgesics; pharmaceutical preparations for the prevention of disorders of the respiratory system; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the prevention and treatment of disorders of the respiratory organs; pharmaceutical preparations in the nature of pharmaceutical compounds for treating respiratory diseases and infections; pharmaceutical products for treating respiratory diseases; inhaled pharmaceutical preparations for the treatment of respiratory diseases and infections; pharmaceutical preparations for treating respiratory diseases and infections.

Pharmaceutical drug development services; development of pharmaceutical preparations and medicines; pharmaceutical research and development; Research and development of medicines.

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Feb 26, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 11, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 11, 2026 OPNR
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Dec 19, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Dec 19, 2025 ABN2
CHANGE OF NAME/ADDRESS REC'D FROM IB
Nov 27, 2025 ADCH
NOTIFICATION OF FINAL REFUSAL EMAILED
Jun 6, 2025 GNFN
FINAL REFUSAL E-MAILED
Jun 6, 2025 GNFR
FINAL REFUSAL WRITTEN
Jun 6, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 11, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 11, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 11, 2025 TROA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 11, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 11, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 11, 2025 TROA
REFUSAL PROCESSED BY IB
Oct 19, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 27, 2024 RFCS
REFUSAL PROCESSED BY MPU
Sep 27, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 24, 2024 RFCR
NON-FINAL ACTION WRITTEN
Sep 23, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 18, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 17, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 17, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 12, 2024 REPR